Clinical Trial Update: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and tolerability of subretinally injected OPGx-BEST1 in patients with Best vitelliform macular dystrophy or autosomal-recessiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Bestrophinopathy
• Best Vitelliform Macular Dystrophy

Drugs mentioned

• OPGx-BEST1

Snippet

Sponsor: Opus Genetics, Inc | Conditions: ARB, BVMD | Phase 1, Phase 2 | Status: RECRUITING